Ethypharm is a specialty pharmaceutical company with European roots, focused on specific Central Nervous System (CNS) diseases and conditions, and on Hospital Injectables.
Discover Ethypharm at a glance
Many of our products are indicated for sensitive situations in which patients either suffer from debilitating conditions such as chronic pain or addiction, or are in a critical state.
All around the world, Ethypharm employees are engaged daily to make the difference for patients’ lives by ensuring they are able to receive the right treatment at the right time and with the right support.
Ethypharm is deeply engaged in the CNS and Hospital Injectable areas, where our medicines treat patients today and our teams work on innovative solutions for tomorrow. Willing to grow beyond our recognised positions in the treatment of severe pain and opioid dependency, we are constantly screening opportunities in search for those which will respond to unmet needs in our two core areas.
Ethypharm is a rapidly transforming company, with a clear strategy and significant growth ambition. Our teams are constantly looking for opportunities to develop our product portfolio, selectively enlarge our geographical coverage and enrich our development pipeline. We are extremely open to discussing potential partnerships. Get to know our R&D and business development (BD) teams and come discuss with us!
Acquisition of Argatroban business in Europe
Ethypharm has entered into an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra®, Arganova®, Novastan®, Exembol®), in Europe.
Read moreEthypharm expands its Mesalazine (Etiasa®) Portfolio in China
Ethypharm is pleased to announce the acquisition of a suppository form of Mesalazine by its Chinese affiliate, Shanghai Ethypharm Pharmaceuticals Ltd, from the Chinese Company Jiangsu Anbison Pharmaceutical.
Read moreEthypharm is growing fast and is always looking to enrich its teams with new talented individuals. We encourage you to visit this site regularly and to follow Ethypharm on LinkedIn to read our latest updates and stay informed about our job opportunities.
Linked